CHESON BRUCE D ET AL: "Bendamustine: rebirth of an old drug", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 27, no. 9, 20 March 2009 (2009-03-20) , pages 1492-1501, XP009124323, ISSN: 0732-183X (B1)

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2003 (2003-11-16), RUMMEL MATHIAS J ET AL: "Bendamustine and rituximab act synergistically in vitro and are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas.", XP002559058, Database accession no. PREV200400172552 & BLOOD, vol. 102, no. 11, 16 November 2003 (2003-11-16), page 104a, 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 06-09, 2003 ISSN: 0006-4971 (B1)

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2008 (2008-11), FISCHER KIRSTEN ET AL: "Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)", XP002559057, Database accession no. PREV200900257032 & BLOOD, vol. 112, no. 11, November 2008 (2008-11), page 128, 50TH ANNUAL MEETING OF THE AMERICAN- SOCIETY-OF-HEMATOLOGY; SAN FRANCISCO, CA, USA; DECEMBER 06 -09, 2008 ISSN: 0006-4971 (B1)

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2008 (2008-11), SALLES GILLES ANDRE ET AL: "A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20(+) Malignant Disease", XP002559059, Database accession no. PREV200900256936 & BLOOD, vol. 112, no. 11, November 2008 (2008-11), page 93, 50TH ANNUAL MEETING OF THE AMERICAN- SOCIETY-OF-HEMATOLOGY; SAN FRANCISCO, CA, USA; DECEMBER 06 -09, 2008 ISSN: 0006-4971 (B1)

HOFFMANN-LA ROCHE: "A Study of RO5072759 With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia", CLINICAL TRIALS, [Online] 6 November 2009 (2009-11-06), XP002559062, Retrieved from the Internet: URL:http://clinicaltrials.gov/ct2/show/NCT 01010061?intr=ro5072759&rank=4> [retrieved on 2009-12-04] (B1)

KNAUF W: "Bendamustine in the treatment of chronic lymphocytic leukemia", EXPERT REVIEW OF ANTICANCER THERAPY 2009 EXPERT REVIEWS LTD. GBR, vol. 9, no. 2, 13 August 2009 (2009-08-13) , pages 165-174, XP8115831, ISSN: 1473-7140 (B1)

WO-A2-2009/053038 (B1)

ROBAK T: "How to improve the treatment outcome in chronic lymphocytic leukemia?", LEUKEMIA RESEARCH, 13 August 2009 (2009-08-13), pages 1-4, XP002559060, DOI: 10.1016/j.leukres.2009.07.033 (B1)

UMANA P ET AL: "Novel 3(rd) generation humanized type IICD20 antibody with glycoengineered fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 11, PART 1, 9 December 2006 (2006-12-09), page 72A, XP008087672, ISSN: 0006-4971 (B1)

UMANA PABLO ET AL.: "GA101, a novel humanized type IICD20 antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumour efficacy and superior tissue B-cell depletion in vivo", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 110, no. 11, abstract:2348, 2007, XP2559271, ISSN: 0006-4971 (B1)

WO-A1-2010/083365 (B1)

WO-A2-2004/103301 (B1)

PLOSKER GREG L ET AL: "Bendamustine A Review of its Use in the Management of Indolent Non-Hodgkin Lymphoma", DRUGS, ADIS INTERNATIONAL LTD, NZ, vol. 68, no. 18, 1 January 2008 (2008-01-01), pages 2645-2660, XP009121943, ISSN: 0012-6667 (B1)